Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Forecasted to Post Q2 2024 Earnings of ($0.06) Per Share

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) – Stock analysts at Wedbush lifted their Q2 2024 earnings estimates for Kiniksa Pharmaceuticals in a research report issued on Tuesday, April 23rd. Wedbush analyst D. Nierengarten now forecasts that the company will post earnings of ($0.06) per share for the quarter, up from their prior estimate of ($0.16). Wedbush has a “Outperform” rating and a $30.00 price target on the stock. The consensus estimate for Kiniksa Pharmaceuticals’ current full-year earnings is ($0.06) per share. Wedbush also issued estimates for Kiniksa Pharmaceuticals’ Q3 2024 earnings at ($0.02) EPS, Q4 2024 earnings at $0.01 EPS, FY2024 earnings at ($0.32) EPS, Q1 2025 earnings at $0.02 EPS, Q2 2025 earnings at $0.03 EPS, Q3 2025 earnings at $0.07 EPS, Q4 2025 earnings at $0.12 EPS, FY2025 earnings at $0.24 EPS, FY2026 earnings at $0.80 EPS and FY2027 earnings at $1.26 EPS.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last posted its earnings results on Tuesday, April 23rd. The company reported ($0.25) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.11). The business had revenue of $79.90 million during the quarter, compared to the consensus estimate of $76.97 million. Kiniksa Pharmaceuticals had a negative return on equity of 7.32% and a net margin of 2.78%. The business’s revenue was up 65.4% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.18) earnings per share.

Several other equities analysts have also recently commented on KNSA. TheStreet upgraded shares of Kiniksa Pharmaceuticals from a “d+” rating to a “c” rating in a research note on Thursday, February 29th. Evercore ISI upped their target price on shares of Kiniksa Pharmaceuticals from $25.00 to $30.00 and gave the company an “outperform” rating in a research note on Wednesday.

Kiniksa Pharmaceuticals Trading Up 1.0 %

NASDAQ KNSA opened at $17.86 on Thursday. The company has a fifty day simple moving average of $19.36 and a 200 day simple moving average of $18.00. The company has a market cap of $1.26 billion, a P/E ratio of 162.38 and a beta of 0.27. Kiniksa Pharmaceuticals has a 1 year low of $10.65 and a 1 year high of $22.09.

Insider Activity

In related news, CAO Michael R. Megna sold 5,126 shares of the stock in a transaction dated Wednesday, February 28th. The shares were sold at an average price of $21.79, for a total transaction of $111,695.54. Following the completion of the sale, the chief accounting officer now owns 17,588 shares in the company, valued at approximately $383,242.52. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, CAO Michael R. Megna sold 5,126 shares of the stock in a transaction dated Wednesday, February 28th. The shares were sold at an average price of $21.79, for a total transaction of $111,695.54. Following the completion of the sale, the chief accounting officer now owns 17,588 shares in the company, valued at approximately $383,242.52. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Sanj K. Patel sold 12,742 shares of the stock in a transaction dated Monday, March 4th. The stock was sold at an average price of $21.49, for a total transaction of $273,825.58. Following the sale, the chief executive officer now owns 70,594 shares of the company’s stock, valued at approximately $1,517,065.06. The disclosure for this sale can be found here. In the last 90 days, insiders sold 33,109 shares of company stock worth $709,929. 54.23% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. IFP Advisors Inc bought a new position in Kiniksa Pharmaceuticals during the 3rd quarter worth approximately $65,000. China Universal Asset Management Co. Ltd. boosted its stake in Kiniksa Pharmaceuticals by 349.7% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 4,097 shares of the company’s stock worth $72,000 after acquiring an additional 3,186 shares during the last quarter. Victory Capital Management Inc. bought a new position in Kiniksa Pharmaceuticals during the 3rd quarter worth approximately $176,000. Dynamic Technology Lab Private Ltd bought a new position in Kiniksa Pharmaceuticals during the 4th quarter worth approximately $213,000. Finally, QRG Capital Management Inc. bought a new position in Kiniksa Pharmaceuticals during the 3rd quarter worth approximately $249,000. Institutional investors own 53.95% of the company’s stock.

About Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.